Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GeneSoft Inc.
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Deal snapshot: Pionyr’s top two candidates are preclinical, but Gilead buys near 50% stake in the hope that myeloid tuners will work in combination with anti-PD-L1 agents in solid tumors.
Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
- Gene Therapy, Cell Therapy